US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma
Aim: To evaluate the cost-effectiveness of polatuzumab vedotin (pola) + bendamustine + rituximab (BR) in relapsed/refractory diffuse large B-cell lymphoma based on the GO29365 trial from a US payer's perspective. Materials & methods: A partitioned survival model used progression-free survival and overall survival data from the GO29365 trial. The base case analysis assumed overall survival was informed by progression-free survival; a mixture cure model estimated proportion of long-term survivors. Results: In the base case, pola + BR was cost-effective versus BR at US$35,864 per quality-adjusted life year gained. Probabilistic and one-way sensitivity analyses showed that the findings were robust. Conclusion: Pola + BR is cost-effective versus BR for the treatment of transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma in the US.
| Errataetall: |
ErratumIn: J Comp Eff Res. 2021 Mar;10(4):337. - PMID 33416405 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Journal of comparative effectiveness research - 9(2020), 14 vom: 20. Okt., Seite 1003-1015 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Betts, Keith A [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 01.04.2021 Date Revised 21.05.2021 published: Print-Electronic ClinicalTrials.gov: NCT02257567 ErratumIn: J Comp Eff Res. 2021 Mar;10(4):337. - PMID 33416405 Citation Status MEDLINE |
|---|
| doi: |
10.2217/cer-2020-0057 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315981857 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315981857 | ||
| 003 | DE-627 | ||
| 005 | 20231225160106.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/cer-2020-0057 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1053.xml |
| 035 | |a (DE-627)NLM315981857 | ||
| 035 | |a (NLM)33028076 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Betts, Keith A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.04.2021 | ||
| 500 | |a Date Revised 21.05.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT02257567 | ||
| 500 | |a ErratumIn: J Comp Eff Res. 2021 Mar;10(4):337. - PMID 33416405 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: To evaluate the cost-effectiveness of polatuzumab vedotin (pola) + bendamustine + rituximab (BR) in relapsed/refractory diffuse large B-cell lymphoma based on the GO29365 trial from a US payer's perspective. Materials & methods: A partitioned survival model used progression-free survival and overall survival data from the GO29365 trial. The base case analysis assumed overall survival was informed by progression-free survival; a mixture cure model estimated proportion of long-term survivors. Results: In the base case, pola + BR was cost-effective versus BR at US$35,864 per quality-adjusted life year gained. Probabilistic and one-way sensitivity analyses showed that the findings were robust. Conclusion: Pola + BR is cost-effective versus BR for the treatment of transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma in the US | ||
| 650 | 4 | |a Evaluation Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a DLBCL | |
| 650 | 4 | |a bendamustine | |
| 650 | 4 | |a cost–effectiveness | |
| 650 | 4 | |a polatuzumab vedotin | |
| 650 | 4 | |a relapsed/refractory | |
| 650 | 4 | |a rituximab | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Immunoconjugates |2 NLM | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 650 | 7 | |a Bendamustine Hydrochloride |2 NLM | |
| 650 | 7 | |a 981Y8SX18M |2 NLM | |
| 650 | 7 | |a polatuzumab vedotin |2 NLM | |
| 650 | 7 | |a KG6VO684Z6 |2 NLM | |
| 700 | 1 | |a Thuresson, Per-Olof |e verfasserin |4 aut | |
| 700 | 1 | |a Felizzi, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Du, Ella X |e verfasserin |4 aut | |
| 700 | 1 | |a Dieye, Ibou |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jia |e verfasserin |4 aut | |
| 700 | 1 | |a Schulz, Mathias |e verfasserin |4 aut | |
| 700 | 1 | |a Masaquel, Anthony S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of comparative effectiveness research |d 2012 |g 9(2020), 14 vom: 20. Okt., Seite 1003-1015 |w (DE-627)NLM218708033 |x 2042-6313 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2020 |g number:14 |g day:20 |g month:10 |g pages:1003-1015 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/cer-2020-0057 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2020 |e 14 |b 20 |c 10 |h 1003-1015 | ||